Moderate To Severe Asthma clinical trials

Explore recruiting moderate to severe asthma clinical trials.

Recruiting moderate to severe asthma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Moderate To Severe Asthma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

C4531029:A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Dose-Ranging Study to Investigate the Efficacy and Safety of PF-07275315 in Adult Participants with Inadequately Controlled Moderate-to-Severe Asthma

Belgium, Hungary, Spain, Bulgaria, Italy, Poland +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Selnoflast in Participants with Moderate to Severe Asthma

Belgium, Netherlands, Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma

Romania, Czechia, Hungary, Poland, Bulgaria

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to assess the efficacy, safety, and tolerability of subcutaneous amlitelimab in adult participants with moderate-to-severe asthma. DRI17509

Italy, Hungary, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

An open label extension study to evaluate the long-term safety and efficacy of subcutaneous lunsekimig in adult participants with asthma who participated in study DRI16762 or ACT18301

Poland, Italy, Belgium, Sweden, Hungary, France +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants with Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids (UMBRIEL)

France, Italy, Greece, Spain, Hungary

Therapeutic exploratory (Phase II) EU CTIS Study details

Moderate To Severe Asthma trials by city

Moderate To Severe Asthma in Toronto Moderate To Severe Asthma in Vancouver Moderate To Severe Asthma in Montreal Moderate To Severe Asthma in Calgary Moderate To Severe Asthma in Edmonton Moderate To Severe Asthma in Ottawa Moderate To Severe Asthma in Winnipeg Moderate To Severe Asthma in Quebec City Moderate To Severe Asthma in Hamilton Moderate To Severe Asthma in Kitchener Moderate To Severe Asthma in London Moderate To Severe Asthma in Halifax Moderate To Severe Asthma in New York Moderate To Severe Asthma in Los Angeles Moderate To Severe Asthma in Chicago Moderate To Severe Asthma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease